ABSTRACT
Ankylosing spondylitis(AS)is a chronic inflammatory rheumatic disease, which belongs to the category of autoimmune diseases and is characterized by inflammatory back pain owing to sacroiliitis and other axial arthritis, as well as bone structural damage and pathological new bone formation. Severe joint and extra-joint lesions have caused great inconvenience and pain, from which patients with ankylosing spondylitis suffer a lot. Therefore researchers have paid more attention to the pathogenesis and drug regulation of ankylosing spondylitis in recent years. At present, the universally recognized pathogenesis of AS includes the influence of genetic factors, immune factors and classical osteogenic pathways, all of which are interrelated and synergistically lead to the progression of AS. In view of its pathogenesis, a series of drugs targeting inflammation have been emerging, including tumor necrosis factor inhibitors, interleukin-17/interleukin-23(IL-17/IL-23)monoclonal antibodies and some anti-rheumatism drugs to relieve the symptoms. Moreover, we also herein highlight the therapeutic necessity of targeting pathological osteogenesis.